Fedratinib exerts antitumor effects against ESCC in vitro, in vivo, and in patient-derived organoid models by suppressing the JAK2–STAT3 signaling axis and its downstream effectors, vimentin, survivin, and cyclin D1. Here, BIRC5 is linked to esophageal squamous cell carcinoma.